| Literature DB >> 20552299 |
B Castagneto1, I Stevani, L Giorcelli, F Montefiore, G L Bigatti, P Pisacco, M F Cosimi.
Abstract
The prognosis for patients with renal cell carcinoma is very poor, with a five-year survival rate of less than 10%. Sorafenib is an orally administered multikinase inhibitor that blocks intracellular kinases in the Raf/MEK/ERK pathway involved in tumor proliferation, and also kinases responsible for angiogenesis, including VEGFr-2, VEGFr-3, Flt-3, PDGFr-β and c-KIT. As a consequence of its limited renal clearance, sorafenib appears to be suitable for patients with advanced kidney cancer and terminal renal failure. The case of a 72-year-old male patient on hemodialysis and receiving sorafenib treatment for mRCC is reported.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20552299 DOI： 10.1007/s12032-010-9595-z
Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064